As suggested in Figure 3, the aberrant expression of SGLT2 in endothelial cells in T2DM or other stresses would lead to intracellular accumulation of glucose: this may clearly explain why SGLT2i are the first type of endothelial protective drugs available today. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.